Bioventus (BVS) Cash from Operations Growth (3y) (2023 - 2026)
Bioventus (BVS) Cash from Operations Growth (3y) (2023 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 182.32 Bn | 175.02 Bn | 6.27 Bn | 4.78% |
| 2 | Stryker | 128.75 Bn | 125.88 Bn | 3.81 Bn | 9.30% |
| 3 | Medtronic | 107.83 Bn | 98.61 Bn | 6.41 Bn | 1.51% |
| 4 | Boston Scientific | 67.61 Bn | 66.15 Bn | 3.61 Bn | 22.35% |
| 5 | Edwards Lifesciences | 48.13 Bn | 44.45 Bn | 1.29 Bn | -48.14% |
| 6 | Dexcom | 28.26 Bn | 27.14 Bn | 750.30 Mn | 50.11% |
| 7 | GE HealthCare Technologies | 27.78 Bn | 25.50 Bn | 1.98 Bn | -14.75% |
| 8 | Smith & Nephew | 26.99 Bn | 26.41 Bn | - | - |
| 9 | Koninklijke Philips | 23.92 Bn | 20.80 Bn | 2.07 Bn | 0.50% |
| 10 | Bioventus | 837.84 Mn | 801.99 Mn | 90.77 Mn | 24.24% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 28, 2026 | 24.24% |
| Dec 31, 2025 | 105.34% |
| Sep 27, 2025 | 475.39% |
| Jun 28, 2025 | 106.65% |
| Mar 29, 2025 | 2.75% |
| Dec 31, 2024 | 13.78% |
| Sep 28, 2024 | -0.86% |
| Jun 29, 2024 | -4.36% |
| Mar 30, 2024 | 30.70% |
| Dec 31, 2023 | -25.85% |
| Sep 30, 2023 | -35.78% |
| Jul 1, 2023 | 11.35% |
| Apr 1, 2023 | -35.90% |